Related Experiment Video

Updated: Nov 8, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.4K

[CME: Giant Cell Arteritis]

Katrin Reiner1, Thomas Fehr1, Jürg Wick1,2

  • 1Innere Medizin, Kantonsspital Graubünden, Chur.

Praxis
|April 28, 2021
PubMed

Insights

Giant cell arteritis (GCA) is a common vasculitis in those over 50, potentially causing vision loss. Tocilizumab offers a safer, more effective treatment alternative to long-term steroid use.

Area of Science:

  • Rheumatology
  • Internal Medicine
  • Vascular Medicine

Background:

  • Giant cell arteritis (GCA) is the most prevalent vasculitis affecting individuals over 50 years old.
  • It primarily targets large blood vessels, leading to cranial and extra-cranial manifestations.
  • Symptoms vary widely, from headaches and visual disturbances to systemic complaints like fatigue and fever.

Purpose of the Study:

  • To review the current understanding of Giant Cell Arteritis.
  • To discuss diagnostic challenges and the critical need for timely intervention.
  • To evaluate treatment options, focusing on steroids and newer alternatives.

Main Methods:

  • Literature review of Giant Cell Arteritis (GCA) diagnosis and treatment.
  • Analysis of current treatment recommendations and guidelines.
  • Comparison of efficacy and safety profiles of different therapeutic agents.

Main Results:

  • GCA presents with diverse symptoms, necessitating prompt diagnosis to prevent irreversible complications like vision loss.
  • Corticosteroids have been the mainstay of treatment for decades but are associated with significant side effects.
  • Tocilizumab has emerged as a more effective and safer therapeutic option.

Conclusions:

  • Early diagnosis and treatment of GCA are crucial to avert severe outcomes.
  • While steroids remain a standard treatment, their adverse effects are a concern.
  • Tocilizumab presents a promising alternative for managing Giant Cell Arteritis, offering improved safety and efficacy.

Keywords:
GCAGiant cell arteritisRZARiesenzellarteriitisTocilizumabVaskulitistocilizumabvasculitis

More Related Videos

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

879
A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application06:53

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

Published on: July 9, 2020

5.2K

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
45
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
162
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
83
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
131